Phaedra  Chrousos net worth and biography

Phaedra Chrousos Biography and Net Worth

Ms. Chrousos currently serves as the Chief Strategy Officer of The Libra Group, where she leads a wide range of strategic initiatives spanning technology transformation to operational development. Headquartered in New York and London, The Libra Group is a diverse, international business group that is active in 35 countries and focused on six business areas: aviation, energy, hospitality, real estate, shipping, and diversified investments. Immediately prior to being appointed Chief Strategy Officer, Ms. Chrousos served as the group's Chief Innovation Officer. Previously, Ms. Chrousos served as a political appointee for the Obama Administration in various roles, including as an Associate Administrator for the General Services Administration. In this capacity, Ms. Chrousos led the Office of Citizen Services and 18F, a digital services team that implemented online service delivery projects and open data initiatives at more than a dozen agencies, including NIH, HHS and the VA. Prior to her departure from the Administration, Ms. Chrousos helped found the Technology Transformation Service, which serves as a foundation for the government's ongoing digital transformation; she served as its Founding Commissioner. Prior to entering public service, Ms. Chrousos co-founded and led two companies, including HealthLeap, a health tech company that reimagined the way doctors and patients communicate. HealthLeap was acquired by Vitals.com 10 months after its launch. She also has several years of consulting experience with The Boston Consulting Group and The World Bank. Ms. Chrousos sits on several non-profit boards, including that of a maternal mental health foundation, and was twice named one of the Federal Government's '50 Women in Technology' by FedScoop and one of Greece's '40 under 40' by Fortune Magazine. Ms. Chrousos holds a B.A. from Georgetown University, an MSc from The London School of Economics and Political Science, and an M.B.A. from Columbia Business School.

What is Phaedra Chrousos' net worth?

The estimated net worth of Phaedra Chrousos is at least $53,121.75 as of June 14th, 2021. Ms. Chrousos owns 12,925 shares of Vanda Pharmaceuticals stock worth more than $53,122 as of March 29th. This net worth evaluation does not reflect any other investments that Ms. Chrousos may own. Learn More about Phaedra Chrousos' net worth.

How do I contact Phaedra Chrousos?

The corporate mailing address for Ms. Chrousos and other Vanda Pharmaceuticals executives is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. Vanda Pharmaceuticals can also be reached via phone at (202) 734-3400 and via email at [email protected]. Learn More on Phaedra Chrousos' contact information.

Has Phaedra Chrousos been buying or selling shares of Vanda Pharmaceuticals?

Phaedra Chrousos has not been actively trading shares of Vanda Pharmaceuticals during the last quarter. Most recently, Phaedra Chrousos sold 2,075 shares of the business's stock in a transaction on Monday, June 14th. The shares were sold at an average price of $19.34, for a transaction totalling $40,130.50. Following the completion of the sale, the director now directly owns 12,925 shares of the company's stock, valued at $249,969.50. Learn More on Phaedra Chrousos' trading history.

Who are Vanda Pharmaceuticals' active insiders?

Vanda Pharmaceuticals' insider roster includes Phaedra Chrousos (Director), Aranthan Jones, II (Insider), Stephen Mitchell (Director), Kevin Moran (CFO), Mihael Polymeropoulos (CEO), and Joakim Wijkstrom (CMO). Learn More on Vanda Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Vanda Pharmaceuticals?

In the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 43,036 shares worth more than $271,424.76. The most recent insider tranaction occured on August, 21st when CMO Joakim Wijkstrom sold 3,724 shares worth more than $21,748.16. Insiders at Vanda Pharmaceuticals own 7.7% of the company. Learn More about insider trades at Vanda Pharmaceuticals.

Information on this page was last updated on 8/21/2023.

Phaedra Chrousos Insider Trading History at Vanda Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2021Sell2,075$19.34$40,130.5012,925View SEC Filing Icon  
See Full Table

Phaedra Chrousos Buying and Selling Activity at Vanda Pharmaceuticals

This chart shows Phaedra Chrousos's buying and selling at Vanda Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vanda Pharmaceuticals Company Overview

Vanda Pharmaceuticals logo
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Read More

Today's Range

Now: $4.11
Low: $3.91
High: $4.19

50 Day Range

MA: $4.00
Low: $3.47
High: $4.61

2 Week Range

Now: $4.11
Low: $3.30
High: $7.00

Volume

1,371,365 shs

Average Volume

980,080 shs

Market Capitalization

$236.49 million

P/E Ratio

82.22

Dividend Yield

N/A

Beta

0.77